BioStock: Tara Heitner is ready to take Cyxone to the next level

Canadian Tara Heitner took office as the new CEO of Cyxone on June 1. The company develops immunomodulating drugs for autoimmune diseases and the portfolio consists of two clinical programmes. Rabeximod is developed as a new therapy for rheumatoid arthritis while T20K is developed for multiple sclerosis. Tara Heitner came to the BioStock Studio and told us about her background, her first impressions of Cyxone and what she already has achieved in her new position.

Watch the interview with Tara Heitner at biostock.se:

https://www.biostock.se/en/biostock-studio-tara-heitner-is-ready-to-take-cyxone-to-the-next-level/

This is a press release from BioStock - Connecting Innovation & Capital:  https://www.biostock.se